Management attributes the more than 350% revenue growth to the success of the company’s EVERx CBD Sports Beverage.
DALLAS, April 16, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE
Puration, Inc. (USOTC: PURA) (“PURA”) today reported over 350% year to year growth between 2017 and 2018. The Company filed its annual financial statement reporting over $1.2 million in revenue for year-end December 31, 2018 with over $500,000 in net profit.
Management attributes the more than 350% revenue growth to the success of the company’s EVERx CBD Sports Beverage. With the company’s recently reported enhanced partnership with Kali-Extracts, (USOTC: KALY) (“KALY”), management expects cannabis beverage diversification and continued rapid growth in 2019. On Friday, this week, April 19th, 2019, PURA management will publish an online shareholder report with more details and insight on the company’s 2018 growth and ongoing anticipated growth in 2019.
The online report is expected to include updates on PURA’s work with KALY to produce new beverages.
PURA is also working closely with the company’s co-packer/partner Alkame Holdings, (USOTC: ALKM) to expand production capacity and keep up with PURA’s growing sales. PURA is also working with North American Cannabis Holdings, (aka USMJ) (USOTC: USMJ) to update PURA’s distribution channels to keep up with USMJ’s online retail sales at USMJ.com and simultaneously meet wholesale demand.
The presentation scheduled for this Friday will also include updates on PURA’s work with ALKM and USMJ.For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.